Jumpcode Genomics is a genome technology company focused on improving the understanding of human disease.
Jumpcode Genomics aims to improve the understanding of human biology and the contribution to disease.
Jumpcode Genomics was founded in 2016 by Keith Brown. The company is headquartered in San Diego, California.
Jumpcode’s patented technology unlocks the power of next-generation sequencing by improving sensitivity, reducing costs, simplifying workflows and removing bias.
Jumpcode's proprietary CRISPRclean technology utilizes the CRISPR/Cas system to deplete unwanted nucleic acid molecules from sequencing libraries. The process fits seamlessly within standard next-generation sequencing workflows and works with most commercially available library preparation solutions.
Jumpcode is backed by Baird Capital, Arboretum Ventures, LYZZ Capital and others. The company raised $21M in a Series B round on Feb 10, 2021. This brings Jumpcode's total funding to $23.5M to date.